Quart Barry D's Form 4 filing
Kiniksa Pharmaceuticals International, plcKNSA · filed Apr 8, 2026
- Accession no.
- 0001384243-26-000008
- Filed
- Apr 8, 2026
- Trade date
- Apr 6, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $345.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Quart Barry DCIK 0001384243 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 6, 2026 | Class A Ordinary Share | MOption exerciseAcquired | +6,901 | $14.33 | +$98,891.33 | 19,447 | Direct | |
| Apr 6, 2026 | Class A Ordinary Share | SSaleDisposed | −6,901 | $50.00F2 | −$345,050 | 12,546 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 6, 2026 | Class A Ordinary Shares | MOption exerciseDisposed | −6,901 | $0.00 | $0 | 26,336 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades through a broker-dealer at prices ranging between $50.00 and $50.015. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
Referenced by the price of 1 transaction in Table I.